Literature DB >> 30450707

Transfemoral PCI skill: Use it or lose it.….But #RadialFirst.

Nitin Barman1, George D Dangas1.   

Abstract

Despite, earlier concerns, is the article by Badri et al., there was no apparent increase in the rate of vascular complications with transfemoral percutaneous coronary intervention (PCI) associated with increasing levels of adoption of transradial PCI by individuals initially identified as primarily femoral operators (> 90% of PCI's via the femoral artery). Compared with the 2010-2011 period, patients undergoing PCI in the United States in 2014-2015 tended to be generally sicker. This fact, coupled with a liberalization in bleeding definition, likely led to an overall increase in the observed rate of vascular complications post-transfemoral PCI (from 1.3 to 1.64%) across the study time period. Despite the extensive body of evidence supporting the use of transradial over transfemoral PCI access, the vast majority (>80%) of primarily femoral operators in the United States have remained low radial adopters and the overall proportion of PCIs performed transradially across this time period by primarily transfemoral operators increased significantly, yet modestly (from 1.3 to 17.8%).
© 2018 Wiley Periodicals, Inc.

Entities:  

Mesh:

Year:  2018        PMID: 30450707     DOI: 10.1002/ccd.27938

Source DB:  PubMed          Journal:  Catheter Cardiovasc Interv        ISSN: 1522-1946            Impact factor:   2.692


  2 in total

1.  Effectiveness of additional X-ray protection devices in reducing Scattered radiation in radial interventions: protocol of the ESPRESSO randomised trial.

Authors:  Remzi Anadol; Moritz Brandt; Nico Merz; Maike Knorr; Majid Ahoopai; Martin Geyer; Damian Krompiec; Phillip Wenzel; Thomas Münzel; Tommaso Gori
Journal:  BMJ Open       Date:  2019-07-03       Impact factor: 2.692

2.  The Rise of Transradial Artery Access for Percutaneous Coronary Intervention in Patients with Acute Coronary Syndromes in Australia.

Authors:  Ryan James Ocsan; Ata Doost; Paul Marley; Ahmad Farshid
Journal:  J Interv Cardiol       Date:  2020-11-27       Impact factor: 2.279

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.